RxDoctor Payments Data

Christopher Price, MD

Anesthesiology · Norfolk, NENPI 1205887510

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 160 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Abbott at 29.3% of the total. Among anesthesiology clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,638in general payments, 2019–2025

Across 160 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$774
  • Boston Scientific$446
  • AbbVie$297
  • Si-bone, Inc.$196
  • Biohaven Pharmaceutical Holding Company Ltd.$168
  • Saluda Medical Americas, Inc.$101
  • plus $655 from 17 others

What the payments were for

  • Food & beverage$2,638100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,638 in reported general payments places this provider in the 90th percentile of 281 anesthesiology providers in Nebraska.

See all anesthesiology providers in Nebraska

Medicare billing

Part B allowed, 2024
$233,273
Medicare patients
591
Services billed
4,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate15$8,707
Fentanyl65$6,303
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen253$5,076
OxycontinOxycodone Hcl12$4,144
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen77$1,517
Gabapentin99$1,102
Tramadol Hcl158$933
Morphine Sulfate ErMorphine Sulfate33$886
Oxycodone Hcl48$580
Nitroglycerin PatchNitroglycerin12$293
Morphine Sulfate12$183
Methadone Hcl11$154
Cyclobenzaprine Hcl19$150
Amitriptyline Hcl14$137
Potassium Chloride13$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$25$8,70715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 anesthesiology providers in Nebraska.

Other anesthesiology in Norfolk

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →